By Jacob Rund
Israeli drugmaker Teva Pharmaceutical Industries Ltd. reported a $19.3 million difference between its CEO’s 2017 compensation and the annual salary of its median worker.
The median annual pay of Teva’s employees totaled $64,081 last year, compared with new CEO Kåre Schultz’s $19.37 million in total compensation, the company said Feb. 12 in a filing with the Securities and Exchange Commission.
Teva’s 302-to-1 “pay ratio” is among the first to trickle in under now-effective SEC disclosure rules, required by the 2010 Dodd-Frank Act.
According to a recent survey from corporate research firm Equilar Inc., Teva’s ratio may be ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.